

FIND Evaluation of Hotgen
Novel Coronavirus 2019-nCoV Antigen Test (Colloidal Gold6
External Report
Version 2.1, [6 May 2022]

Copyright and use of the report

Copyright in this report is the property of FIND (or controlled by FIND). You are free to share, copy and redistribute the material in any medium or format provided that:

- (i) attribution: you must give appropriate credit to FIND and indicate if changes were made, you may do so in any reasonable manner, but not in any way that suggests that FIND endorses you or your use;
- (ii) non-commercial: you may not use the report for commercial purposes; and
- (iii) no derivatives: if you remix, transform, or build upon the materials or report, you may not distribute the modified materials or report unless with express authorization from FIND.

Presentation of data on our website does not impact any data ownership rights and FIND is not responsible for any use by any third party of these data. Data sources are provided.

Evaluation process – private sector engagement

FIND, the global alliance for diagnostics, seeks to ensure equitable access to reliable diagnosis around the world. It works closely with the private and public sectors and receives funding from donors and some of its industry partners. It has internal fire walls, policies and processes to protect it against any undue influence in its work or the publication of its findings.

More information on our policy and guidelines for working with private sector partners can be found here: <https://www.finddx.org/policies/>

For the COVID-19 response, FIND has commissioned independent evaluations of in vitro diagnostics following an Expression of Interest (EOI) process available on FIND’s website by which all test submissions were scored according to their regulatory status and time to market; the manufacturing and distribution capacity of the supplier; and the supplier-reported clinical and analytical performance.

Document history

Document version	Date	Comment
2.1	6 May 2022	First release
2.0	15 Sept 2021	Data for UK added

2.1	5 May 2022	Adding the LOD results for other VOCs
-----	------------	---------------------------------------

1 Product Info:

Manufacturer name	Beijing Hotgen BioTech Co. Ltd.
Test name	Novel Coronavirus 2019-nCoV Antigen Test (Colloidal Gold)
Product code(s)	HGCG134A0140
Pack size(s)	40 tests per kit
Contents of kit	Antigen Test Cassette, Sample extraction buffer, Disposable virus sampling swab
Equipment and consumables required, but not provided	Timer, PPE
Product storage (temperature range)	4-30°C
Shelf-life (months)	18 months
Manufacturing site (country)	China

2 Study details:

Study design:	Prospective diagnostic evaluation studies across multiple, independent sites to determine the accuracy of COVID-19 antigen RDTs, using consecutive enrolment. Interim analyses are performed at 25% and 50% enrolment, and the evaluation is stopped if tests do not meet 95% specificity. Presence of symptoms, date of symptom onset and hospitalization status is collected for all enrolled participants.
Index assays:	Novel lateral flow format tests that detect recombinant SARS-CoV-2 antigens.
Reference method:	Results of the index test are compared to the routine, diagnostic RT-PCR result, which is used for clinical management
Limit of detection:	Analytical sensitivity, i.e. Limit of detection, was performed at the Liverpool School of Tropical Medicine in which standardized serial dilutions of cultured viral isolate were prepared. Proprietary swab provided in the kit was soaked in viral dilution series. Dilutions were tested in triplicate and the LOD was defined as the last dilution where all repeats were interpreted as positive.

Clinical performance:	<p>Sensitivity was calculated as the proportion of true positive results detected by Novel Coronavirus 2019-nCoV Antigen Test (Colloidal Gold) among all positives by the reference method, and reported as a percentage</p> <p>Specificity was calculated as the proportion of true negative specimens, identified as negative by Novel Coronavirus 2019-nCoV Antigen Test (Colloidal Gold) among all negatives by the reference method and reported as a percentage.</p> <p>The 95% confidence intervals were calculated to assess the level of uncertainty introduced by sample size, using the Wilson's score method.</p>
-----------------------	---

3 Evaluation details:

Country of collaborator	Brazil	United Kingdom
Location of clinical site(s) (city, town)	Rio de Janeiro and Guapimirim, state of Rio de Janeiro	Liverpool John Lennon Airport, United Kingdom
Health care level of site(s)	Community testing clinic	Drive through testing centre
Study period (date to date)	11 June – 28 June 2021	13 May – 2 July 2021
Study cohort inclusion/exclusion	<p>Adults in community meeting national suspect definition</p> <p>Provided informed consent</p>	<p>Inclusion:</p> <ul style="list-style-type: none"> • 18 years or older, who are undergoing testing for COVID-19 • Symptomatic for COVID-19 • Provided informed consent <p>Exclusion:</p> <ul style="list-style-type: none"> • Asymptomatic • Younger than 18 years
Sample type, antigen test	Nasal swabs	Nasopharyngeal swab
Reference PCR method	Lab-developed assay based on the US CDC protocol, which targets two regions (N1 and N2) of the nucleocapsid (N)	TaqPath™ COVID-19 CE-IVD RT-PCR Kit (ThermoFisher Scientific)

	gene of SARS-CoV-2 (https://www.fda.gov/meda/134922/download)	
Sample type, PCR test	Nasopharyngeal (NP) swab	Combined Nasal (anterior nares) and oropharyngeal swabs

4 Results:

4.1 Study cohort

Country	Brazil	UK
Total N (valid PCR results)	453	248
Age [mean (min-max), N]	39.4 (18-100), 453	40.5 (18-76), 248
Gender [%F, (n/N)]	40.1%, (272/454)	57.5%, (142/247)
Symptoms present [%Yes, (n/N)]	97.4%, (442/454)	100%, (248/248)
Hospitalized (n, % Yes)	Not applicable	Not applicable
Days from symptom onset [median (Q1-Q3); N]	3 (3-5), 442	2 (1-3), 245
Days < 0-3 (n, %)	231, 52%	199, 81%
Days 4-7 (n, %)	195, 44%	33, 13%
Days 8+ (n, %)	16, 4%	13, 5%
Positivity [%, (n/N)]	23%, (106/454)	27%, (68/248)
PCR Ct [median (Q1-Q3); N]	20.4 (17.7-23.8), 106	21.2 (18.5-24.1), 68
Ct > 33 (n, %)	1, 1%	1, 1%
Ct > 30 (n, %)	7, 7%	1, 1%
Ct > 25 (n, %)	17, 16%	10, 15%

4.2 Estimation of Clinical Performance

Country	Brazil	UK
Clinical Sensitivity (95% CI), N	88.7% (81.2, 93.4), 106	80.9% (70, 88.5), 68
Sensitivity days ≤ 7 , N	90.1% (82.7, 94.5), 101	84.4% (73.6, 91.3), 64
Sensitivity Ct ≤ 33 , N	89.5% (82.2, 94), 105	80.6% (69.6, 88.3), 67
Sensitivity Ct ≤ 25 , N	95.5% (89, 98.2), 89	82.8% (71.1, 90.4), 58
Clinical Specificity (95% CI), N	100% (98.9, 100), 348	99.4% (96.9, 99.9), 180
Invalid rate (% , n/N)	0% (0/454)	0% (0/248)

4.3 Estimation of analytical performance

- Supplier-reported LOD = $2.5 \times 10^{2.2}$ TCID₅₀/ml ~ 5.59×10^2 TCID₅₀/ml ~ 2.81×10^2 pfu/ml (isolate BetaCoV/Beijing/IME-BJ01/2020-01)
- Verified LOD

Variant (lineage)	Lowest dilution detected	Verified LOD concentration	Viral Copy equivalent
UK wild type (B1)	5.0×10^2 pfu/ml ~ 7.05×10^2 TCID ₅₀ /ml	5.0×10^2 pfu/ml	1.18×10^6 genome copies/ml applied to test
Alpha (B.1.1.7)	1.0×10^3 pfu/ml ~ 1.41×10^3 TCID ₅₀ /ml	1.0×10^3 pfu/ml	2.1×10^4 genome copies/ml applied to test
Gamma (P1)	2.5×10^3 pfu/ml ~ 3.525×10^3 TCID ₅₀ /ml	2.5×10^3 pfu/ml	1.73×10^6 genome copies/ml applied to test
Delta (B.1617.2)	2.5×10^2 pfu/ml ~ 3.525×10^2 TCID ₅₀ /ml	2.5×10^2 pfu/ml	9.90×10^5 genome copies/ml applied to test
Omicron (BA.1)	5.0×10^3 pfu/ml ~ 7.05×10^3 TCID ₅₀ /ml	5.0×10^3 pfu/ml	8.83×10^5 genome copies/ml applied to test

Note: viral dilution was applied directly to the test cassette, not to the provided swab